Monoclonal antibody treatment of solid tumors: A coming of age

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 11, 2000, Pages 64-70

  Murray, J L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RADIOISOTOPE;

ANTIBODY PRODUCTION; BREAST CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CHIMERA; CONFERENCE PAPER; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; MEDICAL ONCOLOGY; RADIOIMMUNOTHERAPY;

EID: 0034470347     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging
2. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECTTc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study
3. Monoclonal antibody-based therapies of leukemia and lymphoma
4. Monoclonal antibody therapy of cancer
5. Monoclonal antibodies: They're more and less than you think
6. Monoclonal antibodies in cancer treatment: A review of recent progress
7. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
8. Animal cell cycle
9. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/ neu overexpressing human breast cancer xenografts
10. Monoclonal antibodies for treating cancer
11. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
12. Ganglioside CD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
13. Mouse monoclonal IgC3 antibody detecting CD3 ganglioside: A phase I trial in patients with malignant melanoma
14. Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma
15. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
16. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer
17. Transfectomas provide novel chimeric antibodies
18. Replacing the complementarity-determining regions in a human antibody with those from a mouse
19. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors
20. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen of malignant ascites cells
21. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment
22. Effect of recombinant interferon alpha on pharmacokinetics, biodistribution, toxicity and efficacy of 131 I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial
23. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
24. Humanization of an anti-p185HER2 antibody for human cancer therapy
25. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer
26. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women in HER2 overexpression who had relapsed following chemotherapy for metastatic breast cancer
27. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
28. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER-2-overexpressing (HER+) metastatic breast cancer (MBC)
29. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
30. Rituximab immunotherapy for non-Hodgkin's lymphoma
31. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
32. Phase I/II study of Rituxan in chronic lymphocytic leukemia (CLL)
33. Rituximab therapy in previously treated Waldenstrom's macroglobulinemia: Preliminary evidence of activity
34. In vivo purging and adjuvant immunotherapy with rituximab PBSC transplant for NHL
35. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
36. Radioimmunotherapy of cancer: Arming the missiles
37. Radiolabeled monoclonal antibodies for cancer therapy and diagnosis: Is it really a chimera?
38. 131I]anti-B1 (anti-CD20) antibody
39. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
40. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
41. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma
42. Single-chain antigen-binding proteins
43. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody
44. A novel method for the detection of necrotic lesions in human cancers
45. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity
46. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177Lu-CC49
47. Intrathecal 131I-labeled antitenascin monoclonal antibody 81 C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results